Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults

Purpose of review This review focuses on the safety of oral tenofovir disoproxil and emtricitabine (FTC) combination for HIV preexposure prophylaxis (PrEP) in adults. Recent findings Gastrointestinal adverse events are common after treatment initiation but usually resolve within weeks. Although clinical trials did not report an increased risk of serious renal adverse events or tubulopathy, meta-analyses suggest that tenofovir disoproxil -FTC is associated with a slight but non-clinically relevant decline in estimated glomerular filtration rate (eGFR). A decline to less than 60 mL/min remains a rare event, which mainly occurs in users with an age>50 years or a baseline creatinine clearance
Source: Current Opinion in HIV and AIDS - Category: Infectious Diseases Tags: PREP (PRE-EXPOSURE PROPHYLAXIS): Edited by Jean-Michel Molina Source Type: research